Semaglutide Research for Fatty Liver Disease (MASH)
An evidence-based overview of research examining Semaglutide in the context of fatty liver disease (mash). This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis in August 2025. The ESSENCE interim histology analysis found MASH resolution without fibrosis worsening in 62.9% versus 34.3% with placebo and at least one stage of fibrosis improvement without MASH worsening in 36.8% versus 22.4%. The mechanism in human MASH is not fully established; weight loss and other GLP-1-mediated pathways may contribute. Histologic improvements at week 72 do not yet establish long-term clinical outcomes. The US accelerated approval is specifically for Wegovy injection in adults with noncirrhotic MASH and F2-F3 fibrosis. Confirmation of clinical benefit remains pending from the ongoing ESSENCE trial.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.